DNA content analysis of the cytokeratin+ CD44+/CD90+ tumor population, a subset shown to be highly tumorigenic in other epithelial cancers [6], [11], [19], revealed an imatinib-mediated right-shift in DNA profile consistent with the expansion of early S-phase cells and cell cycle arrest (supplementary Figure S4, bottom right). Here, CD44 is linked to neoplasm.